Answers are grounded in this paper and cite their sources.
Chronic hepatitis C virus (HCV) infection remains a major public health challenge. This retrospective study evaluated the seroprevalence of anti-HCV antibodies in a sample of 5346 patients tested in Alexandria (Teleorman County) between 2021 and 2024 using laboratoryenzyme immunoassays. The overall seropositivity rate was 1.53 % (82 cases), with no significant differences between females and males (1,70 % vs. 1,11%, p = 0,1417; OR = 1,54). Age distribution indicated a zero prevalence in the 18–34 age group (0.00 %) and a peakvalue of 3.70 % in the ≥65 age group (p = 2,75 × 10-14), confirming the persistence of a cohort effect. Temporal dynamics demonstrated a stable annual rate (1.89% in 2021, 1.40 % in 2022, 1.55 % in 2023, and 1.59 % in 2024, p = 0.9262), highlighting the need for continuedpopulation screening campaigns and sustained access to DAA therapies.
No takes yet. Share an insight, caveat, or question.
Mariana Luminiţa Olaru (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: